Afuco™ Anti-Human VEGFC ADCC Recombinant Antibody (VGX100), ADCC Enhanced

CAT#: AFC-635CL

Anti-VEGFC ADCC Enhanced Antibody (VGX100) is an ADCC enhanced antibody produced by our Afuco™ platform. VGX-100 is a human antibody that acts against the human vascular endothelial growth factor (VEGF)-C protein. Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, VGX-100 is developing for a number of other cancer indications, and as an agent to treat front-of the-eye diseases.

Gene Expression
Figure 1 RNA cell line category: Cell line enhanced.

Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Applications
  • Neut, FuncS
  • Related Disease
  • Glioma; Prostate Cancer; Solid Tumors

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Applications

  • Application Notes
  • VEGF-C Neutralization with Blocking Antibody
    VEGF-C was blocked using neutralizing monoclonal anti-VEGF-C (VGX-100). VGX-100 was commercially supplied, based on a signed material transfer agreement; and according to the manufacturer, VGX-100 binds to and precipitates all forms of VEGF-C including full-length, partially processed, and mature forms in both the human and mouse. To block VEGF-C, 20 mg/kg (in total 0.1 mL volume) of VGX-100 was injected from the day before surgery, through the intraperitoneal route and on alternate days subsequently up to 2 weeks. Control mice received 0.1 mL of normal saline intraperitoneally.

Target

  • Alternative Names
  • VEGFC; vascular endothelial growth factor C; VRP; Flt4-L; LMPH1D; FLT4 ligand DHM; vascular endothelial growth factor-related protein
REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS
Inquiry
Navs

Customer Review

Submit a review or a question

There are currently no Customer reviews or questions for AFC-635CL. Click the button above to contact us or submit your feedback about this product.
Breast cancer biomarkers at key points during disease progression
Robust immune response
I've used VGX100 in my oncology research, and the enhanced ADCC activity has significantly improved our results compared to traditional anti-VEGFC antibodies. The immune response is much more robust, which is critical for our therapeutic development.
Breast cancer biomarkers at key points during disease progression
Consistent potency and stability
We followed the recommended storage guidelines for VGX100 and observed consistent potency and stability over a six-month period. Proper storage is indeed crucial for maintaining its efficacy.
Breast cancer biomarkers at key points during disease progression
Better results with enhanced Fc region
The enhanced Fc region in VGX100 has made a noticeable difference in our efficacy studies. The level of immune cell engagement and subsequent tumor cell lysis was significantly higher compared to standard antibodies.

Q&As

  1. What specific laboratory assays can be used to verify the ADCC enhancement of Afuco™ Anti-Human VEGFC ADCC Recombinant Antibody (VGX100)?

    A: ADCC enhancement for VGX100 can be verified through various assays such as the Chromium Release Assay, where target cells are labeled with chromium-51 and the lysis of these cells by effector cells in the presence of VGX100 is measured. Additionally, flow cytometry-based cytotoxicity assays and ELISA for cytokine release can also provide evidence of ADCC activity.

  2. How does this Antibody (VGX100) influence angiogenesis in tumor environments?

    A: VGX100 targets VEGFC to inhibit its function, which is crucial for angiogenesis in tumor environments. By blocking VEGFC, VGX100 effectively reduces the formation of new blood vessels that supply nutrients and oxygen to the tumor, thereby inhibiting tumor growth and metastasis.

  3. How does the ADCC Enhanced antibody differ from traditional anti-VEGFC antibodies in terms of activation of the immune response?

    A: Afuco™ Anti-Human VEGFC ADCC Recombinant Antibody (VGX100), ADCC Enhanced is specifically engineered for ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) enhancement. Unlike traditional anti-VEGFC antibodies, VGX100 not only neutralizes VEGFC but also optimizes the Fc region to more effectively engage immune effector cells, leading to an amplified and targeted immune response against VEGFC-expressing cells.

View the frequently asked questions answered by Creative Biolabs Support.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Article title:
DOI/PubMed URL:
Email:
Name:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Related Signaling Pathways

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

See other products for "VEGFC"

Select a product category from the dropdown menu below to view related products.

Specific Inquiry
Go to compare Add to compare

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare